Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 191 - 200 of 243
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Tehran University
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Reversible inhibition of sperm under guidance (RISUG)
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Indian Council for Medical Research, Indian Institute of Technology, Kharagpur
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
ROC
Alternative Name: Ulipristal acetate (UPA) Oral
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: HRA Pharma, NICHD
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: MCR-165, Medicated Contraceptive Ring-165
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: C31G Vaginal Gel
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: Adamis Pharmaceuticals
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Depo-subQ + Uniject
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Pfizer, PATH, USAID
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: SCHIELD Biodegradable MPT Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: RTI International
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 11 - 20 of 70
Alternative Name: ATPase Plasma Membrane Calcium Transporting 4, PMCA4, Plasma Membrane Calcium-Transporting ATPase 4, PMCA4b, PMCA4x, Matrix-Remodeling-Associated Protein 1, Sarcolemmal Calcium Pump, EC 7.2.2.10, EC 3.6.3.8, EC 3.6.3
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification

Pages

Displaying 1 - 10 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting, Short-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: ARC; triple hormone contraceptive; Triple OC
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: ANI Pharmaceuticals, Pantarhei Bioscience
Development Stage: Phase II
Alternative Name: Suspensories
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: Centre Hospitalier Universitaire de Toulouse, France
Development Stage: Phase II
Alternative Name: LNG Biodegradable Implant for Contraception, Yale BDI
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Yale University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III

Pages

Displaying 41 - 50 of 52
Alternative Name: MCR-165, Medicated Contraceptive Ring-165
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed
Alternative Name: Depo-subQ + Uniject
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Pfizer, PATH, USAID
Development Stage: SRA/WHO PQ Approved
Alternative Name: Flomax
User: Male
Hormonal: No
Duration Type: Pericoital
Delivery Method: Oral
Development Stage: SRA/WHO PQ Approved
Alternative Name: IUD HBCu375/MCu375 and TCu380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tianjin Medical Instrument Factory
Development Stage: Marketed
Alternative Name: Triclovera; OSKB -1
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: PT. Tunggal Idaman Abdi
Development Stage: Marketed
Alternative Name: LNG Contraceptive IUS 12 (LCS12)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council, Theramex, Rockefeller Foundation
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Development Stage: Marketed
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed

Pages

CSV